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Introduction. During the natural evolution of prostate cancer in patients treated with prostatectomy many of them develop
biochemical relapse and need radiation treatment.
Objective. To ﬁnd potential predictor factors to response to radiotherapy in prostate cancer patients with biochemical relapse
after prostatectomy.
Methods. We have selected the 59 prostate cancer patients treated with prostatectomy from 2006 to 2008 that were submitted
after biochemical relapse. We have analyzed the following variables to see their impact on the response to the radiotherapy: pN,
Gleason [≤7 (3 + 4) vs. ≥7 (4 + 3)], irradiated volume, dose delivered (<70Gy vs. 70Gy), hormonal treatment (yes/no), and PSA level
before radiotherapy. Follow up: mean 49 months (range 30–69).
Results. Two patients (3.39%) died (one for prostate cancer). 57 patients (96.61%) are still alive, of which 39 (66.10%) remain free of
disease; 13 (22.03%) developed biochemical relapse and 6 (10.20%) distant metastases. PSA pre-radiotherapy was the only variable
analyzed that showed a statistically signiﬁcant incidence p=0.0002 (HR 1254, 95% CI 0.107, 0.345). These results indicate that
for every unit that PSA pre-radiotherapy raises, the risk of developing biochemical relapse is 25% higher. In our series, patients
with PSA> of 1.65ng/ml had a risk of recurrence 3.95 times higher than those with a PSA ≤1.65 (p=0.0049). Gleason, hormonal
treatment and dose delivered: no showed statistically signiﬁcant p values but their survival curves show a clear positive trend
in patients with Gleason ≤7 (3 + 4), who received hormonal treatment and in which dose was ≥70Gy. Volume treated and, pN:
showed no statistical signiﬁcance.
Conclusions. In our series the only variable that has demonstrated statistically signiﬁcance as a predictor factor was PSA pre-
radiotherapy (p=0.0002). Patients with PSA pre-radiotherapy >1.6ng/ml had 3.95 times more risk to developing biochemical
relapse.
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Background. The aim was to obtain the time to nadir of PSA (nPSA) in patients with disease free of recurrence in low risk carcinoma
of prostate cancer, treated with radical external beam radiotherapy (EBRT). And to study the bounce PSA.
Materials and methods. A group of 45 patients, with low risk prostate cancer, (it was considered low risk prostate cancer, those
patients with PSA≤10ng/ml, Gleason=6 or stage T1–T2), who were treated in the years 2007–2009 either using external-beam
RT (78Gy) to prostate volume, without blockage androgen. The treatment was carried out in a lineal accelerator using photons
of 18 MV, with standard technique and fractionation. After baseline prostate-speciﬁc antigen determination (PSApreRT), PSA
was assessed 3 months after the start RTE, and after it was measured every six months. The median follow-up after RT was 27
months with a rate (21–51 months). A bounce was deﬁned by a minimum rise in PSA of 0.4ng/ml over a 6-month period, followed
by a decrease without therapeutic intervention.
Results. The median PSApreRT was 7.35. Median nPSA value was 0.51ng/ml (limits: 0–1.52) and the median time elapsed between
PSApreRT and nPSA has been of 22 months (limits: 9–45). PSA bounce >0.5ng/ml was noted in 18% of patients. After 6 months
the values return close to nPSA values. The median length of time until the ﬁrst PSA bounce was 24 months. None patient had
relapse biochemical by the Phoenix deﬁnition.
Conclusion. In patients with low risk prostate cancer, when EBRT is used as monotherapy, time to nadir is very long. In our cohort
were found benign PSA bounces. Our study reinforces the need for adequate follow-up to ensure accurate estimates of treatment
efﬁcacy and to avoid unnecessary secondary interventions.
http://dx.doi.org/10.1016/j.rpor.2013.03.507
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Introduction. Hypognadism is awell known factor related to the adipose tissue increase, cardiovascular risk and skeletalmyopathy.
Aim. Quantitative CT scans have shown a fat redistribution and a decrease in bone density secondary to hypogonadism. Andro-
genic blockade (AB) induces an hypogonadism status and thus prostate cancer patients are expected to show a fat redistribution
